openPR Logo
Press release

Indian diabetes market to reach US$ 1.4 bn by 2015, predicts IMARC

09-20-2010 07:58 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: IMARC Group

With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction of the global sales, IMARC expects this market to surge in the future.

In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015.

Unlike Non-Insulin’s, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin.

Report Highlights

•A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to US$1.4 Billion by 2015.
•In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 306 Million. This represented a highly fragmented market with USV being the leading player with a 14% share.
•USV’s Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market with sales worth nearly US$ 10.5 Million
•IMARC expects around 15 new Drugs to be launched in the Non-Insulin Anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV Inhibitor and GLP-1 Agonist classes.
•The Insulin Market was worth US$ 117 Million in 2009. Abbott was India’s biggest player accounting for 61% of the total sales.
•Sanofi Aventi’s Lantus (Insulin Glargine) represented one of the fastest growing drugs in the last five year and registered sales worth nearly 11 Million in 2009
•The total number of diabetes patients in India is expected to reach 87 Million by 2030. Around 56% of these patients will be from urban regions.

Forecasts: The report provides forecasts on:
•Number of diabetes patients
•Diagnosis and treatment rates in India
•Diabetes market
•Non-Insulin Anti-diabetics market
•Glitazones
•Biguanides
•Sulphonylureas
•Alpha-Glycosidase Inhibitors
•DPP-IV Inhibhitors
•GLP-1 Agonists
•Glinides
•All other Non-Insulin Anti-diabetic classes
•Insulin market

Competitive Landscape: This section covers:
•2005-2009 sales and market shares of top players in the diabetes market
•2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market
•2005-2009 sales and market shares of top players in various Non-Insulin drug classes
•2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin drug classes
•2005-2009 sales and market shares of top players in the Insulin market
•2005-2009 sales of top drugs comprising the portfolio of key players in the Insulin market.

Key Questions Answered in this report
•What is the total size of the diabetes population in India and what are it’s characteristics?
•What are the diagnosis and drug treatment rates for diabetes in India?
•What are the key factors driving the growth of diabetes medication in India?
•What is the size and breakup of the total diabetes market in India?
•What is the size and breakup of the total Non-Insulin diabetes market in India?
•What is the size and breakup of the total Insulin market in India?
•Who are the key players in the Indian diabetes market and how have they performed?
•What is the outlook of the Indian diabetes market in the next five years?
•Which new products are expected to be launched in the next five years?
•Which therapy classes will show the highest growth in the next five years?
•What are the road blocks in the Indian diabetes market?

To get the full version of the "Indian diabetes market report and outlook for 2010-2015" please get in touch with us by emailing us at sales@imarcgroup.com or you can call us on +91-11-43095788

About IMARC

For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

IMARC Group Delhi
press@imarcgroup.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Indian diabetes market to reach US$ 1.4 bn by 2015, predicts IMARC here

News-ID: 145083 • Views:

More Releases from IMARC Group

Dimethyl Ether Market Valuation to Reach USD 15.73 Billion by 2033 - Industry Expanding at a CAGR of 8.09%
Dimethyl Ether Market Valuation to Reach USD 15.73 Billion by 2033 - Industry Ex …
Market Overview: The dimethyl ether market is experiencing significant growth momentum, driven by increasing demand for cleaner fuel alternatives, expanding applications in various industries, and supportive government policies promoting sustainable energy solutions. According to IMARC Group's latest research publication, "Dimethyl Ether Market Size, Share, Trends and Forecast by Raw Material, Application, End-Use Industry, and Region, 2025-2033", the global dimethyl ether market size reached USD 7.22 Billion in 2024. Looking forward, IMARC
Glucometer Manufacturing Plant Report 2025: Unit Setup, Cost and Requirements, Project Economics
Glucometer Manufacturing Plant Report 2025: Unit Setup, Cost and Requirements, P …
Setting up a glucometer manufacturing plant requires thorough market research alongside a minute understanding of numerous operating factors such as unit processes, purchasing of raw materials, utility supply, infrastructure creation, equipment and technology specifications, human resource planning, logistics, and cash outlay. IMARC Group's report titled "Glucometer Manufacturing Plant Cost Analysis Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for establishing a
Acetyltributyl Citrate Production Plant Cost Analysis Report 2025: Project Details and Machinery Requirements
Acetyltributyl Citrate Production Plant Cost Analysis Report 2025: Project Detai …
Establishing an acetyltributyl citrate plant will require a thorough market research, as well as a hard-granular understanding of various processes in the business such as unit operations, provision of raw materials, utilities, facility setup, equipment and technologies, human resources, logistics, and economics. IMARC Group's report titled "Acetyltributyl Citrate Production Plant Cost Analysis Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for
eSIM Market Size, Share, Growth And Trends Report 2025-2033
eSIM Market Size, Share, Growth And Trends Report 2025-2033
eSIM Market Overview: The eSIM (embedded SIM) market is expanding rapidly as digital connectivity and IoT adoption reshape global communication technologies. Unlike traditional SIM cards, eSIMs are embedded directly into devices, enabling remote provisioning and seamless switching between network operators. This technology is gaining traction across smartphones, wearables, tablets, connected cars, industrial IoT, and smart home devices. The growing need for flexible, secure, and cost-efficient connectivity is driving market growth, along

All 5 Releases


More Releases for Insulin

Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Insulin Pumps Market Share, Trends and Growth Analysis By Type (Traditional Insu …
Insulin Pumps Market is expected to register a CAGR of 15.5% and acquire the market value of USD 11.5 Billion by 2028 during forecast period 2023-2032. Insulin pumps are discreet, electronic medical devices that can be tucked beneath clothing or fastened to a belt. In order to regulate the rise in blood glucose levels, the pump is used to deliver controlled quantities of insulin within the body at regular intervals
Insulin Patch Pumps Market Report 2018: Segmentation by Insulin Type (Bolus Insu …
Global Insulin Patch Pumps market research report provides company profile for Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA, Valeritas, Becton Dickenson & Company, Insulet Corporation, Johnson & Johnson, Medtrum Technologies Inc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,
Insulin pump Market Explore Future Growth 2018-2026 by Global Type-Traditional i …
Insulin pump is a portable device attached to the body that continuously delivers preset amounts of short or rapid acting insulin in the body to control diabetes. Insulin therapy is required in type 1 diabetes and sometime in type 2 diabetes. It serves as an effective alternative to insulin injections. Furthermore, insulin pump delivers the insulin according to the need of body as basal rate, where small amount of insulin